Abstract Library

#2881 Patient-Derived Tumor Xenograft Combined with Chemotherapy Drug Sensitivity Test in a Patient with Pancreatic Neuroendocrine Carcinoma

Introduction: Pancreatic neuroendocrine carcinoma (p-NEC) with liver metastasis has a poor prognosis. The treatment is mainly chemotherapy which is now still a huge challenge on NEC with high ki-67 index.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bai J

Authors: Bai J, Tang Q,

Keywords: Pancreatic neuroendocrine carcinoma, chemotherapy, Doxorubicin+mitomycin+loplatin, patient-derived tumor xenograft, Carbon ion,

#2794 Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs

Introduction: Several classes of antibiotics have been associated with anti-proliferative effects on cancer cells; however, there is no data on this regarding pNETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Lagler H, Mazal P, Kretschmer-Chott E, Haug A,

Keywords: pancreatic neuroendocrine tumors, treatment, somatostatin analogs, antibiotics, lanreotide,

#2785 Inhibition of Cyclin Dependent Kinases Overcomes MYC-Driven Secondary Resistance to Everolimus in Digestive NETs

Introduction: Dysregulation of the mTOR pathway in digestive neuroendocrine tumours (d-NETs) led to the introduction of Everolimus (EVE) as treatment. EVE significantly increases PFS, but most patients acquire resistance, due to activation of feedback loops.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Capurso G

Authors: Terracciano F, Capone A, Montori A, Pilozzi E, Arcidiacono P,

Keywords: mTOR, Myc, resistance, pathway, RNA-seq,

#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mpilla G

Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, Philip P,

Keywords: pak4, nampt, mtor, pancreatic neuroendocrine tumors, kpt-9274,

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,